Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc reaffirms FY 2014 outlook; gives FY 2014 adjusted net income outlook below analysts' estimates; gives Q2 2014 revenue outlook below analysts' estimates


Thursday, 8 May 2014 04:03pm EDT 

Emergent BioSolutions Inc:Reaffirms FY 2014 outlook.Expects FY 2014 total revenue of $415 to $445 mln.Expects FY 2014 net income of $30 to $40 mln.Expects FY 2014 adjusted net income of $40 to $50 mln.Expects Q2 2014 total revenue of $95 to $110 mln.FY 2014 revenue of $439 mln, net income of $51 mln - Thomson Reuters I/B/E/S.Q2 2014 revenue of $119 mln - Thomson Reuters I/B/E/S. 

Related Company News

Company Quote

27.05
0.07 +0.26%
19 Dec 2014